Print this page    •   Back to Web version of article

10 Top Studies Whose Impact Will Last Well Beyond CROI 2013

By Josep M. Llibre, M.D., and Benjamin Young, M.D., Ph.D.

March 14, 2013

Benjamin Young, M.D., Ph.D., and Josep M. Llibre, M.D.

Benjamin Young, M.D., Ph.D. (left), and Josep M. Llibre, M.D., take a break during CROI 2013 to grab some charred meat at a Grindhouse Killer Burgers in Atlanta. Photo credit: Dr. Schuyler Livingston

The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) has come and gone. While we enjoyed a healthy dose of warm southern hospitality, a world-class aquarium and great food, a lot of ground-breaking medical and scientific news was presented. If you didn't have the opportunity to make the trip to Atlanta (only ~4,000 were given that coveted admission), here's a quick review of what we thought were the top 10 presentations (divided across seven topic areas) likely to have a lingering impact.

Table of Contents

Josep M. Llibre, M.D., is in the HIV Unit of the "Lluita contra la SIDA" Foundation at University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. Dr. Llibre has received funding for research or payment for conferences or participation on advisory boards from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, and ViiV Healthcare.

Benjamin Young, M.D., Ph.D., is vice president and chief medical officer of the International Association of Providers of AIDS Care based in Washington, D.C., and an adjunct professor at the Josef Korbel School of International Studies at the University of Denver. Dr. Young has received consulting or speaking fees from Bristol-Myers Squibb, Cerner Corporation, Gilead Sciences, GlaxoSmithKline, Merck & Co., Monogram Biosciences and ViiV Healthcare. He has received research funding from Bristol-Myers Squibb Company, Cerner Corporation, Gilead Sciences, GlaxoSmithKline, Merck & Co., and ViiV Healthcare.


Copyright © 2013 Remedy Health Media, LLC. All rights reserved.




This article was provided by TheBodyPRO.com. It is a part of the publication The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013). You can find this article online by typing this address into your Web browser:
http://www.thebodypro.com/content/70878/10-top-studies-whose-impact-will-last-well-beyond-.html

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.